Altimmune Class Action Lawsuit: Submit Your Information [Aug. 2025]

SUBMIT YOUR INFORMATION

Introduction to the Altimmune Class Action Lawsuit

If you suffered substantial losses and wish to serve as lead plaintiff of the Altimmune class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].

Lead plaintiff motions for the Altimmune class action lawsuit must be filed with the court no later than October 6, 2025.

SUBMIT YOUR INFORMATION

Allegations in the Altimmune Class Action Lawsuit

Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity, metabolic, and liver diseases.

The Altimmune class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

1. Defendants created the false impression that they possessed reliable information pertaining to the results of Altimmune’s IMPACT Phase 2b metabolic associated steatohepatitis (“MASH”) trial;
2. Altimmune failed to meet an important statistical significance marker relating to the fibrosis reduction primary endpoint; and
3. Altimmune concealed higher responses in the placebo group, which defendants knew or should have known would negatively impact the IMPACT Phase 2b MASH trial’s topline results.

The Altimmune class action lawsuit further alleges that on June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH and disclosed that “[a]lthough we saw positive trends in fibrosis improvement, statistical significant was not achieved on this endpoint.”  On this news, the price of Altimmune stock fell more than 53%, according to the complaint.

SUBMIT YOUR INFORMATION